Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 12448654)

1.

Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.

Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G.

Invest New Drugs. 2002 Nov;20(4):377-82.

PMID:
12448654
2.

Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.

Rivera E, Chang JC, Semiglazov V, Burdaeva O, Kirby MG, Spector T.

Clin Breast Cancer. 2014 Feb;14(1):26-30. doi: 10.1016/j.clbc.2013.08.018. Epub 2013 Nov 1.

PMID:
24183612
3.

A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.

Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA.

Cancer Chemother Pharmacol. 2012 Dec;70(6):875-81. doi: 10.1007/s00280-012-1979-7. Epub 2012 Sep 28.

PMID:
23053263
4.

[Combined effect of gemcitabine and lomustine in mice with intracranial transplanted lymphosarcoma LIO-1].

Stukov AN, Filatova LV, Gershanovich ML, Semiglazova TIu, Tarasenkova AA, Latinova DKh, Vershinina SF, Zargarova NI.

Vopr Onkol. 2012;58(3):394-7. Russian.

PMID:
22888657
5.

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI.

Cancer Invest. 2011 Nov;29(9):617-25. doi: 10.3109/07357907.2011.621912.

6.

A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.

Jones SF, Bendell JC, Infante JR, Spigel DR, Thompson DS, Yardley DA, Greco FA, Murphy PB, Burris HA 3rd.

Clin Adv Hematol Oncol. 2011 Mar;9(3):225-30.

PMID:
21475129
7.

Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma.

de Lima Lopes G Jr, Dicksey JS, Peters WP, Palalay M, Chang AY.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1067-73. doi: 10.1007/s00280-011-1588-x. Epub 2011 Feb 23.

PMID:
21344302
8.

A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

Yardley DA, Peacock NW, Dickson NR, White MB, Vázquez ER, Foust JT, Grapski R, Hendricks LK, Scott WL, Hainsworth JD.

Clin Breast Cancer. 2010 Jun;10(3):217-23. doi: 10.3816/CBC.2010.n.029.

PMID:
20497920
9.

Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).

Roehrig S, Wein A, Albrecht H, Konturek PC, Reulbach U, Männlein G, Wolff K, Ostermeier N, Hohenberger W, Hahn EG, Boxberger F.

Med Sci Monit. 2010 Mar;16(3):CR124-131.

PMID:
20190682
10.

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.

Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I.

J Clin Oncol. 2009 Nov 20;27(33):5499-505. doi: 10.1200/JCO.2008.21.5384. Epub 2009 Oct 26.

11.

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.

Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.

Am J Clin Oncol. 2009 Aug;32(4):348-52. doi: 10.1097/COC.0b013e31818c08ff.

PMID:
19363436
12.

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F, Smith H, Eberhardt S, Maestas A, Lu H, Verschraegen C.

Invest New Drugs. 2009 Apr;27(2):153-8. doi: 10.1007/s10637-008-9172-x. Epub 2008 Sep 5.

PMID:
18773144
13.

EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.

Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D; National Cancer Research Institute Anal Sub Group and Colorectal Clinical Oncology Group.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26. doi: 10.1016/j.ijrobp.2007.12.012. Epub 2008 May 9.

PMID:
18472366
15.

A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.

Karampeazis A, Vamvakas L, Agelaki S, Kentepozidis N, Papadimitraki E, Gioulbasanis I, Vardakis N, Ignatiadis M, Mavroudis D, Georgoulias V.

Oncology. 2006;71(5-6):347-53. Epub 2007 Sep 3.

PMID:
17785992
16.
17.

Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.

Gagel B, Piroth M, Pinkawa M, Reinartz P, Krohn T, Kaiser HJ, Stanzel S, Breuer C, Asadpour B, Schmachtenberg A, Eble MJ.

BMC Cancer. 2007 Jun 28;7:112.

18.

A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.

Amarantidis K, Houhouli K, Papatheodorou K, Miloussis A, Matthaios D, Chatzaki E, Lyrantzopoulos N, Tsaroucha A, Tentes A, Kakolyris S.

Oncol Res. 2006;16(6):281-7.

PMID:
17476973
19.

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.

Hensley ML, Dizon D, Derosa F, Venkatraman E, Sabbatini P, Chi DS, Dupont J, Colevas AD, Spriggs D, Aghajanian C.

Invest New Drugs. 2007 Aug;25(4):335-41. Epub 2007 Mar 16.

PMID:
17364235
20.

A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.

Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I, Joensuu H, Sjöström-Mattson J; Finnish Breast Cancer Group.

Clin Breast Cancer. 2006 Dec;7(5):401-5.

PMID:
17239265
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk